Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 761-781 , December 2007

The Arkansas approach to therapy of patients with multiple myeloma

  • Bart Barlogie, MD, PhD (Professor of Medicine and Pathology, Tommy May Chair in Oncology, Director, Myeloma Institute for Research and Therapy)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel./Fax: +1-501-526-2273.
    • ,
  • Elias Anaissie, MD (Vice Chair and Director of Supportive Care)
    • ,
  • Frits van Rhee, MD, PhD (Professor of Medicine, Director of Clinical Research)
    • ,
  • Mauricio Pineda-Roman, MD (Assistant Professor of Medicine, Director of Faculty Affairs)
    • ,
  • Maurizio Zangari, MD (Associate Professor of Medicine)
    • ,
  • John Shaughnessy, PhD (Professor of Medicine, Director, Lambert Laboratory of Myeloma Genetics, Director of Basic Research)
    • ,
  • Joshua Epstein, DSc (Professor of Medicine)

References 

  1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–824
  2. Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67:1298–1301
  3. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869–872
  4. Ventura GJ, Barlogie B, Hester JP, et al. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. Bone Marrow Transplantation. 1990;5:265–268
  5. Jagannath S, Vesole DH, Glenn L, et al. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992;80:1666–1672
  6. Vesole DH, Barlogie B, Jagannath S, et al. High dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood. 1994;84:950–956
  7. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793
  8. Barlogie B, Tricot G, van Rhee F, et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology. 2006;135:1365–2141
  9. Pui C-H, Evans WE. Drug therapy: treatment of acute lymphoblastic leukemia. The New England Journal of Medicine. 2006;354:166–178
  10. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. Blood. 1992;79:2827–2833
  11. Fermand JP, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 1989;73:20–23
  12. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. British Journal of Haematology. 1998;102:495–502
  13. Ellison R, Holland J, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32:507–523
  14. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. The Journal of the American Medical Association. 1969;208:1680–1685
  15. Barlogie B, Tricot G, Anaissie E, et al. Effect of adding thalidomide to the treatment of multiple myeloma with tandem autotransplants. The New England Journal of Medicine. 2006;10:1021–1030
  16. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology. 2007;138:176–185
  17. Powles R, Raje N, Cunningham D, et al. Maintenance therapy for remission in myeloma with Intron A following high dose melphalan and either an autologous bone marrow transplantation or pheripheral stem cell rescue. Stem Cells. 1995;13:114–117
  18. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine. 1999;341:1565–1571
  19. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492–494
  20. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine. 2003;348:2609–2617
  21. Zangari M, Barlogie B, Jacobson J, et al. VTD regimen comprising Velcade + thalidomide and added DEX for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma relapsing after autologous transplant. Blood. 2003;102:236a;830 [abstract]
  22. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20–32
  23. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology. 2003;21:2732–2739
  24. Hideshima T, Chauhan D, Richardson P, et al. Identification and validation of novel therapeutic targets for multiple myeloma. Journal of Clinical Oncology. 2005;23:6345–6350
  25. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250–4256
  26. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028
  27. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692–1700
  28. Shaughnessy J, Zhan F, Burington B, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–2284
  29. Zhan F, Huang Y, Van Hemert R, et al. The Gene Expression Signatures (GEP) of Whole Bone Marrow Biopsies (Bx) from Patients with Multiple Myeloma (MM) in Remission Reflect Disease Risk and Therapy. Blood. 2005;106:1547;[abstract]
  30. Shaughnessy J, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. British Journal of Haematology. 2007;137:530–536
  31. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. Journal of Clinical Oncology. 2007;25:1121–1128
  32. Tian E, Zhan F, Walker R, et al. The role of Wnt/beta-catenin signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine. 2003;349:2483–2494
  33. Haessler J, Shaughnessy JD, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clinical Cancer Research, in press.
  34. Pineda-Roman M, Bolejack V, Arzoumanian V, et al. Complete Resonse in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smoldering disease. British Journal of Haematology. 2007;136:393–399
  35. van Rhee F, Bolejack V, Hollmig K, et al. High serum free-light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827–832
  36. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. The New England Journal of Medicine. 1996;335:91–97
  37. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine. 2003;348:1875–1883
  38. Attal M, Harousseau J-L, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. The New England Journal of Medicine. 2003;349:2495–2502
  39. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633–2638
  40. Richardson P, Mitsiades C, Schlossman R, et al. New drugs for myeloma. The Oncologist. 2007;12:663–689
  41. Arzoumanian V, Barlogie B, Pineda-Roman M, et al. Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM). Blood. 2006;108:3561;[abstract]
  42. Pineda-Roman M, Fox M, Hollmig K, et al. Retrospective analysis of fractionated high-dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM). Blood. 2006;108(18S):3102;[abstract]
  43. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377–2380
  44. Pineda-Roman M, Anaissie E, Zangari M, et al. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in more than 3000 patients. Journal of Clinical Oncology. 2007;25:8043;[abstract]
  45. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. British Journal of Haematology. 2001;114:822–829
  46. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54
  47. Fassas T, Kiwan E, Roberts J. Metronomic chemoimmunotherapy in a patient with refractory Waldenström's macroglobulinemia. Leukemia & Lymphoma. 2005;46:1675–1677
  48. Finger D, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinatory of cell groth and cell cycle progression. Oncogene. 2004;23:3151–3171
  49. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. British Journal of Haematology. 1995;95:349–353
  50. Shaughnessy JD, Zhan F, Huang Y, et al. In vivo changes in gene expression profiles (GEP) after bortezomib (V) for multiple myeloma (MM): differential effects on plasma cells (PC) and microenvironment (ME). ASCO Meeting Abstracts. 2006;24:7603
  51. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalan-based autotranplants for multiple myeloma linked to poor hematopoietic stem cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 2007 Sep 25;Epub ahead of print

PII: S1521-6926(07)00071-0

doi: 10.1016/j.beha.2007.09.005

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 761-781 , December 2007

Article Tools

* Image Usage & Resolution